Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a Bone-Strengthening infusion given right after hip surgery prevent a second break?

NCT ID NCT05025293

Disease control Sponsor: Lene Bergendal Solberg Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This trial compares giving zoledronate, a yearly intravenous bone-strengthening drug, within 5 days of hip fracture surgery versus waiting 3 months. The goal is to see if early treatment is as safe and effective at reducing bone turnover and preventing future fractures. Participants are adults over 50 who had a low-energy hip fracture and surgery within 72 hours. The study measures bone turnover markers and recovery outcomes like mobility and delirium.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Zoledronic acid (an intravenous bisphosphonate given once yearly to strengthen bones)
What this could lead to
If early zoledronate works as well as delayed treatment, hip fracture patients could start protecting their bones sooner, potentially reducing the risk of another fracture.
What could go wrong
This is a non-inferiority trial, so it may show early treatment is not as good. Risks include kidney issues, low calcium, and side effects from the infusion.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

228 people

The number who actually took part.

Started

Dec 2021

Finished

Jun 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Low energy hip fracture * Surgery within 72 hours * \>50 years old norwegian * Women age 50-60 must be postmenopausal or not pregnant * Acceptable kidney function (estimated GFR \>=35) and calcium levels * Fit to complete the follow-up judged by the recruiting physician * Signed informed consent by the patient or the next of kin Exclusion Criteria: * Metal in the opposite hip * Anti-osteoporosis treatment with bisphosphonates, denosumab, teriparatide, abaloparatide or romosozumab within the last 10 years * Glucocorticoid therapy * Too sick to receive treatment with zoledronate judged by the recruiting or treating physician * Any other contraindication listed on the SmPC of the IMP(s) including pregnancy * Participating in another trial that might affect the current study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hip fractures are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

delirium hip fracture osteoporosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hip fractures Osteoporosis

Contacts and locations

Locations

  • Oslo University Hospital

    Oslo, Oslo, 0424, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.